Oncotelic Therapeutics, Inc. (OTCMKTS:OTLC) Sees Large Growth in Short Interest

Oncotelic Therapeutics, Inc. (OTCMKTS:OTLC) was the recipient of a significant growth in short interest in the month of June. As of June 30th, there was short interest totaling 94,847 shares, a growth of 320.0% from the June 15th total of 22,583 shares. Approximately 0.0% of the shares of the company are short sold. Based on an average trading volume of 483,454 shares, the days-to-cover ratio is presently 0.2 days.

Oncotelic Therapeutics Stock Performance

OTLC traded down $0.00 during midday trading on Friday, hitting $0.04. 74,204 shares of the company were exchanged, compared to its average volume of 277,382. The firm has a market capitalization of $17.67 million, a price-to-earnings ratio of 0.07 and a beta of -0.27. Oncotelic Therapeutics has a 1-year low of $0.01 and a 1-year high of $0.11. The company’s 50 day simple moving average is $0.05 and its 200 day simple moving average is $0.05. The company has a current ratio of 0.11, a quick ratio of 0.11 and a debt-to-equity ratio of 0.01.

Oncotelic Therapeutics (OTCMKTS:OTLC) last announced its quarterly earnings results on Wednesday, April 15th. The company reported $0.59 earnings per share for the quarter.

About Oncotelic Therapeutics

Oncotelic Therapeutics is a clinical‐stage biotechnology company dedicated to the development of novel oncolytic virotherapy and diagnostic platforms for cancer treatment. The company’s lead therapeutic candidate, telomelysin (OBP‐301), is an oncolytic adenovirus engineered to selectively replicate in telomerase‐positive tumor cells, offering a targeted approach to destroying cancerous tissue while sparing healthy cells. In addition to its therapeutic pipeline, Oncotelic markets TelomeScan, a proprietary diagnostic assay designed to detect and enumerate viable circulating tumor cells by exploiting telomerase activity.

Originally founded with technology licensed from Japanese research institutions, Oncotelic has established collaborative relationships in both the United States and Asia to advance its clinical and commercial programs.